2 results
Approved WMORecruiting
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor anNTRK1/2/3, ROS1, or ALK gene rearrangement
Approved WMORecruiting
The main objective of this study is to determine the optimal second line treatment strategy in Caucasian patients with metastatic pancreatic cancer, whereby the hypothesis is, based on studies conducted in the Asian population, that the combination…